It doesn’t happen often—in fact, hardly ever—that a company decides to stop studying a promising drug it’s developing and then a few months later asks the Food and Drug Administration (FDA) to consider approving it. But that’s exactly what occurred with aducanumab, an Alzheimer’s drug being developed by U.S. pharmaceutical company Biogen and its partner, Eisai, a Japanese pharma outfit.